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AbsTRACT
background: Ankaferd BloodStopper (ABS) is a standardized herbal compound 
consisting of 5 different plant extracts. ABS, as a topical medicinal product, has been 
approved by the Turkish Ministry of Health for the management of dermal, external 
postsurgical and postdental surgery bleedings. 
Objective: The aim of this study was to assess the hemostatic effect of ABS in 
an experimental epistaxis model. 
Methods: Adult female New Zealand rabbits were used in this study. Standard-
ized full-thickness mucosal wounds were created to provide bleeding on the right and 
left side of the nasal septum of rabbits with a 3-mm surgical punch. To stop bleeding, 
the wounds were treated with topical ABS on one side and with topical isotonic saline 
solution as a control on the other side of the nasal septum. Investigators were blinded 
to treatment. The duration of bleeding was measured in order to compare the hemo-
static effect with ABS or topical isotonic saline solution. The wounds were observed 
for the duration of bleeding in order to compare the hemostatic effect of ABS with 
isotonic saline solution and acute adverse effects (AEs) for 30 minutes by a researcher 
blinded to treatment groups.
Results: Six rabbits (mean weight, 2.6 kg [range, 2.3–3.1 kg]) were used in 
this study. Mean (SD) bleeding time in the wounds administered ABS (98 [17] sec) 
was significantly less than that of the controls (266 [36] sec; P = 0.004). No AEs were 
observed up to 30 minutes after study initiation.
Conclusion: This study suggests that ABS may be more effective in reducing 
time to hemostasis when compared with isotonic saline solution in this epistaxis model in 
rabbits. (Curr Ther Res Clin Exp. 2010;71:105–110) © 2010 Excerpta Medica Inc.
Key words: Ankaferd BloodStopper, epistaxis, hemostasis, experimental.
105_CTRV71N2_kurtaran.indd   105 4/7/2010   3:34:04 PM
Current Therapeutic Research
106
InTROduCTIOn
Epistaxis, or nasal bleeding, is one of the most significant problems in otorhinolaryn-
gology.1 Approximately 5% to 10% of the world population experiences some form 
of spontaneous nasal bleeding annually. Incidence of epistaxis appears to occur more 
often in males than in females and is more predominant at ages <10 and >50 years.2,3 
The high frequency of epistaxis is related to the rich blood supply of the nasal septum 
and its vulnerability to external trauma. Between 90% and 95% of epistaxis originates 
from the anterior nasal septum, and the great majority of these arise in Little’s area, 
which is located over the anterior-inferior portion of the nasal septum. Little’s area has 
a rich complex of vessel anastomosis (Kisselbach’s plexus) originating from the inter-
nal and external carotid arteries.4,5 Severe epistaxis has traditionally been treated 
effectively with nasal packing, cautery, and topical hemostatic agents.5,6 However, 
these methods can predispose infection, septal perforation, and aspiration. This has led 
investigators to continue to look for alternative methods for treating epistaxis.
Ankaferd BloodStopper (ABS)* is a unique folkloric medicinal plant extract, which 
has historically been used in Turkish traditional medicine as a hemostatic agent.7 ABS 
comprises a standardized mixture of the plants, Glycyrrhiza glabra, Vitis vinifera, Alpinia 
officinarum, Urtica dioica, and Thymus vulgaris. Each of these plants has some effect on the 
endothelium, blood cells, angiogenesis, cellular proliferation, vascular dynamics, and 
cell mediators.5 ABS, as a medicinal topical product, has been approved by the Turkish 
Ministry of Health for the management of dermal, external postsurgical and postdental 
surgery bleeding when administered immediately. The in vivo hemostatic effect of ABS 
has been evaluated in rats as well as in a swine model.8,9 When applied to the cut tails 
of rats, topical ABS reduced both the duration and the amount of bleeding volume by 
68.4% and 54.6%, respectively.8 Bilgili et al9 found that a 40-second application of 
ABS tampon was sufficient to stop bleeding of skin lacerations, while 1.5- and 3.5-minute 
applications were used to control hemorrhage from the saphenous vein and artery, re-
spectively, in a porcine model. Data on the efficacy of ABS in human gastrointestinal 
system bleeding is limited to case reports.10–13 Kurt et al10 found that the topical use of 
ABS via endoscopic intervention completely controlled human upper gastrointestinal 
bleeding within seconds. Ibis et al12 used topical ABS for a bleeding solitary rectal ulcer 
to successfully control bleeding.
We hypothesize that ABS might be an effective hemostatic agent for nasal bleed-
ing. To evaluate this hypothesis, we conducted a study aimed at investigating the in 
vivo hemostatic effect of ABS in an experimental epistaxis model.
MATeRIAls And MeThOds
Ankaferd bloodstopper
ABS was purchased from Trend Teknoloji Ilac AS, Istanbul, Turkey. It has been 
approved in Turkey to be used topically for the management of external hemorrhage 
and bleeding from dental surgery.7 ABS solution is a combination of plant extracts. The 
*Trademark: Ankaferd Health Products Ltd., Istanbul, Turkey.
105_CTRV71N2_kurtaran.indd   106 4/7/2010   3:34:04 PM
 107
h. Kurtaran et al.
relative ratio of plant extracts in ABS is as follows: A officinarum, 7 mg/100 mL; 
G glabra, 9 mg/100 mL; T vulgaris, 5 mg/100 mL; U dioica, 6 mg/100 mL; and 
V vinifera, 8 mg/100 mL.
Animals
Adult female New Zealand rabbits were used in this study. The animals were 
purchased locally and kept in a room at a constant temperature (22°C ± 4°C) with a 
12-hour light/dark cycle, normal diet ad libitum, and free access to tap water. All 
experiments were carried out in accordance with the European Community Council 
Directive of November 1986 (86/609/EEC)14 and were approved by the Fatih Uni-
versity Medical School Ethics Committee.
experimental design
All animals were sedated with intramuscular 5 mg/kg xylocaine hydrochloride 
(23.32 mg/mL; Bayer, Istanbul, Turkey) and 50 mg/kg ketamine chloride (Parker 
Davis and Company, Detroit, Michigan).
Standardized, full-thickness, mucosal wounds were created with a 3-mm surgical 
punch on the nasal septum of the rabbits. The surgical punch was applied to the nasal 
mucosa over the right and left anterior part of the nasal septum using slight pressure. 
The punch was rotated 90° clockwise and 90° counterclockwise to yield a full-thickness 
mucosal cut without harming the septal cartilage. The circular mucosal injury re-
sulted in bleeding within 1 to 2 seconds in all cases. Wounds were treated randomly 
(either right or left) with topical ABS on one side and with topical isotonic saline solu-
tion (control) on the other side of the nasal septum. Cotton sticks were used for the 
application of topical ABS and isotonic saline solution. ABS (0.2 mL) and isotonic 
saline (0.2 mL) solution were adsorbed to cotton sticks and pressed gently into the 
wounds for 1 second every 30 seconds until the bleeding stopped. Although topical 
application is recommended by the manufacturer, no detailed application method was 
described and this method was first used in this study. ABS or isotonic saline solution 
was applied as soon as the bleeding started. The wounds were observed for the dura-
tion of bleeding in order to compare the hemostatic effect of ABS with isotonic saline 
solution and acute adverse effects (AEs) for 30 minutes by an investigator blinded to 
treatment. The rabbits were euthanized at the end of the study period.
bleeding Assessment
Duration of bleeding was defined as the time that passed after the start of bleeding 
(ie, full-thickness wounds were created) to cessation of bleeding. Bleeding start and stop 
times were measured in seconds with a chronometer by one investigator blinded to 
treatment (A.A.O.).
statistical Analysis
All statistical analyses were done using SPSS software version 13.0 (SPSS Inc., 
Chicago, Illinois). Descriptive statistics were used to generate the means and standard 
deviations of each group. Statistical significance was set as P < 0.05 and the statisti-
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cally significant results were evaluated with the Mann-Whitney U test. Sample size 
was defined by using a similar study.15
ResulTs
Six adult female New Zealand rabbits (mean weight, 2.6 kg [range, 2.3–3.1 kg]) were 
used in the study.
Duration of bleeding (bleeding time) was measured for both wounds (Table). Mean 
(SD) bleeding time in the wounds administered ABS was 98 (17) seconds. Mean 
bleeding time in the control group was 266 (36) seconds. Mean bleeding time in the 
wounds administered ABS was significantly shorter than in the wounds administered 
isotonic saline solution (P = 0.004).
Rabbits were monitored for 30 minutes after the completion of the experiment. No 
AEs were observed for either application.
dIsCussIOn
The present in vivo study on rabbits suggests that topically administered ABS has 
a hemostatic effect on rabbit epistaxis. ABS was found to be effective in shortening 
the duration of bleeding when compared with isotonic saline solution in a rabbit 
epistaxis model.
In the present study, we preferred a simple, reproducible epistaxis model that cre-
ates mucosal wounds of the same size and depth with a surgical biopsy punch, as de-
veloped by Singer et al.15 This epistaxis rabbit model may contribute to research at-
tempting to find a reliable bleeding time. Singer et al developed a porcine epistaxis 
model and found that octylcyanoacrylate (OCA) was effective in achieving hemostasis. 
The effectiveness of OCA was observed to be statistically significant when compared 
with a control group after full heparinization. The results of the present study suggest 
Table.  Bleeding times in rabbits with epistaxis on the right and left side 
of the nasal septum treated with topical Ankaferd BloodStopper 
(ABS)* or administered isotonic saline solution (control). Data 
are in seconds.
Rabbit No. ABS Control
1 101 212
2 78 241
3 95 294
4 125 264
5 107 312
6 82 276
Mean (SD) 98 (17)† 266 (36) 
*Trademark: Ankaferd Health Products Ltd., Istanbul, Turkey.
† P = 0.004 versus the control group.
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that topical ABS was effective as a hemostatic agent in a rabbit epistaxis model with-
out heparinization. In our study, the bleeding time was significantly shorter compared 
with those administered topical isotonic saline solution. Although there was a statisti-
cally significant effect of ABS in bleeding time, all bleeding times in both groups 
were near or under 5 minutes. Therefore, it is unclear if ABS would be effective in 
wounds requiring intervention.
A recent in vitro study suggested that addition of ABS to plasma did not affect the 
individual coagulation factors II, V, VII, VIII, IX, X, XI, and XIII.7 The basic mecha-
nism of action for ABS is the formation of an encapsulated protein network that provides 
focal points for vital erythrocyte aggregation. Ankaferd-induced protein network for-
mation with blood cells, particularly erythrocytes, covers the primary and secondary 
hemostatic system.7 
ABS was administered topically to the cut tail of rats by Kosar et al8 to determine 
the effectiveness of ABS. In both the acetylsalicylic acid– and enoxaparin-treated rats, 
topical ABS reduced both the duration and also the amount of bleeding volume. 
Cipil et al16 found that topical ABS administration to an amputated leg shortened the 
duration of bleeding markedly in both untreated and warfarin-treated rats.
This agent should be investigated further in clinical trials to determine whether 
ABS might be effective in hemostasis of epistaxis. 
limitations
There are several limitations of this study such as small sample size and the lack of 
a heparinized group. A study with a bigger sample size and the addition of a third 
group with wounds performed following heparinization to yield intervention-required 
bleeding would provide more objective results.
COnClusIOn
This study found that hemostasis was achieved faster with ABS compared with isotonic 
saline solution in a model of epistaxis in rabbits. 
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